Lineage Cell Therapeutics, Inc. (LCTX) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 5 Buy.
Analysts estimate Earnings Per Share (EPS) of $-0.06 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.09 vs est $-0.06 (missed -59.5%). 2025: actual $-0.28 vs est $-0.30 (beat +5.3%). Analyst accuracy: 79%.
LCTX Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to Lineage Cell Therapeutics, Inc. in the past 3 months
EPS Estimates — LCTX
79%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$0.09
vs Est –$0.06
▼ 37.3% off
2025
Actual –$0.28
vs Est –$0.30
▲ 5.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — LCTX
77%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.009B
vs Est $0.008B
▲ 13.9% off
2025
Actual $0.015B
vs Est $0.010B
▲ 32.0% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
